Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to Buy at StockNews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Saturday.

Other equities research analysts have also issued research reports about the company. BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. UBS Group boosted their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target on the stock. Bank of America boosted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. Finally, Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $976.41.

Regeneron Pharmaceuticals Price Performance

REGN opened at $896.82 on Friday. The business’s 50-day moving average is $953.01 and its two-hundred day moving average is $891.10. Regeneron Pharmaceuticals has a 1 year low of $684.80 and a 1 year high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm has a market capitalization of $98.43 billion, a PE ratio of 25.81, a price-to-earnings-growth ratio of 2.60 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the previous year, the firm earned $10.96 earnings per share. The firm’s quarterly revenue was up .6% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals will post 38.59 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the sale, the director now owns 18,382 shares of the company’s stock, valued at $17,540,472.04. The disclosure for this sale can be found here. Insiders sold a total of 13,729 shares of company stock valued at $13,124,641 in the last three months. 8.83% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently made changes to their positions in the company. Eudaimonia Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 1.2% in the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 11 shares in the last quarter. Ronald Blue Trust Inc. grew its holdings in Regeneron Pharmaceuticals by 18.8% in the 3rd quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 12 shares in the last quarter. Drive Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals by 4.0% in the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 12 shares in the last quarter. MCF Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares in the last quarter. Finally, LCM Capital Management Inc grew its holdings in Regeneron Pharmaceuticals by 2.5% in the 4th quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock valued at $427,000 after buying an additional 12 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.